{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:52:07Z","timestamp":1787507527095,"version":"build-2736575974"},"reference-count":36,"publisher":"American Veterinary Medical Association (AVMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2015,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    \u2014To determine survival time for dogs with splenic hemangiosarcoma treated with splenectomy alone, identify potential prognostic factors, and evaluate the efficacy of adjuvant chemotherapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design<\/jats:bold>\n                    \u2014Retrospective case series.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Animals<\/jats:bold>\n                    \u2014208 dogs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Procedures<\/jats:bold>\n                    \u2014Medical records were reviewed, long-term follow-up information was obtained, and survival data were analyzed statistically.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    \u2014154 dogs were treated with surgery alone, and 54 were treated with surgery and chemotherapy. Twenty-eight dogs received conventional chemotherapy, 13 received cyclophosphamide-based metronomic chemotherapy, and 13 received both conventional and metronomic chemotherapy. Median survival time of dogs treated with splenectomy alone was 1.6 months. Clinical stage was the only prognostic factor significantly associated with survival time. When the entire follow-up period was considered, there was no significant difference in survival time between dogs treated with surgery alone and dogs treated with surgery and chemotherapy. However, during the first 4 months of follow-up, after adjusting for the effects of clinical stage, survival time was significantly prolonged among dogs receiving any type of chemotherapy (hazard ratio, 0.6) and among dogs receiving both conventional and metronomic chemotherapy (hazard ratio, 0.4).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\n                    \u2014Clinical stage was strongly associated with prognosis for dogs with splenic hemangiosarcoma. Chemotherapy was effective in prolonging survival time during the early portion of the follow-up period. Combinations of doxorubicin-based conventional protocols and cyclophosphamide-based metronomic protocols appeared to be more effective than either type of chemotherapy alone, but prolongations in survival time resulting from current protocols were modest.\n                  <\/jats:p>","DOI":"10.2460\/javma.247.4.393","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T11:53:31Z","timestamp":1438257211000},"page":"393-403","source":"Crossref","is-referenced-by-count":134,"title":["Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001\u20132012)"],"prefix":"10.2460","volume":"247","author":[{"given":"Kristin M.","family":"Wendelburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Lyn","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine E.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah A.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia H.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"J Am Vet Med Assoc","first-page":"56","article-title":"Canine hemangiosarcoma: retrospective analysis of 104 cases","volume":"186","author":"Brown","year":"1985"},{"key":"ref2","series-title":"J Am Vet Med Assoc","first-page":"706","article-title":"Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985)","volume":"193","author":"Prymak","year":"1988"},{"key":"ref3","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1939-1676.1989.tb03092.x","article-title":"Splenomegaly in dogs: predictors of neoplasia and survival after splenectomy","volume":"3","author":"Johnson","year":"1989"},{"key":"ref4","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5326\/15473317-34-5-417","article-title":"Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991\u20131993)","volume":"34","author":"Wood","year":"1998"},{"key":"ref5","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2460\/javma.231.10.1550","article-title":"Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997\u20132004)","volume":"231","author":"Kim","year":"2007"},{"key":"ref6","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1939-1676.1991.tb00943.x","article-title":"Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin and cyclophosphamide) in dogs with hemangiosarcoma","volume":"5","author":"Hammer","year":"1991"},{"key":"ref7","series-title":"Clin Cancer Res","first-page":"1165","article-title":"Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial","volume":"1","author":"Vail","year":"1995"},{"key":"ref8","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1939-1676.2004.tb00162.x","article-title":"Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma","volume":"18","author":"Sorenmo","year":"2004"},{"key":"ref9","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1939-1676.1997.tb00085.x","article-title":"Pathologic factors affecting postsplenectomy survival in dogs","volume":"11","author":"Spangler","year":"1997"},{"key":"ref10","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","article-title":"Surgery and doxorubicin in dogs with hemangiosarcoma","volume":"10","author":"Ogilvie","year":"1996"},{"key":"ref11","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.2460\/javma.245.12.1382","article-title":"Risk factors for perioperative mortality in dogs undergoing splenectomy for splenic masses: 539 cases (2001\u20132012)","volume":"245","author":"Wendelburg","year":"2014"},{"key":"ref12","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1939-1676.1993.tb01033.x","article-title":"Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide","volume":"7","author":"Sorenmo","year":"1993"},{"key":"ref13","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1939-1676.2000.tb02247.x","article-title":"Canine hemangiosarcoma treated with standard chemotherapy and minocycline","volume":"14","author":"Sorenmo","year":"2000"},{"key":"ref14","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1939-1676.2007.tb02936.x","article-title":"Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma","volume":"21","author":"U'Ren","year":"2007"},{"key":"ref15","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1476-5829.2011.00266.x","article-title":"A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma","volume":"9","author":"Teske","year":"2011"},{"key":"ref16","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5326\/JAAHA-MS-5954","article-title":"VAC protocol for treatment of dogs with stage III hemangiosarcoma","volume":"49","author":"Alvarez","year":"2013"},{"key":"ref17","series-title":"Can Vet J","first-page":"237","article-title":"Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study","volume":"54","author":"Kahn","year":"2013"},{"key":"ref18","series-title":"Vet Comp Oncol","first-page":"221","article-title":"Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma","volume":"8","author":"Wiley","year":"2010"},{"key":"ref19","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5326\/JAAHA-MS-5525","article-title":"Treatment with DAV for advanced-stage hemangiosarcoma in dogs","volume":"47","author":"Dervisis","year":"2011"},{"key":"ref20","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1939-1676.2007.tb03019.x","article-title":"Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs","volume":"21","author":"Lana","year":"2007"},{"key":"ref21","series-title":"Guidance for Industry\u2014E10. Choice of control group and related issues in clinical trials, 2.5.2"},{"key":"ref22","series-title":"Virch Arch Pathol Anat","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF00437598","article-title":"Factor VIII related antigen as an endothelial cell marker in benign and malignant diseases","volume":"391","author":"Sehested","year":"1981"},{"key":"ref23","series-title":"Withrow & MacEwen's small animal clinical oncology","first-page":"679","article-title":"Miscellaneous tumors: section A\u2014hemangiosarcoma","author":"Thamm","year":"2013"},{"key":"ref24","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1748-5827.1988.tb01907.x","article-title":"Metastatic pattern in dogs with splenic haemangiosarcoma: clinical implications","volume":"29","author":"Waters","year":"1988"},{"key":"ref25","series-title":"Vet Radiol Ultrasound","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1740-8261.2002.tb01003.x","article-title":"Cellular features of sonographic target lesions of the liver and spleen in 21 dogs and a cat","volume":"43","author":"Cuccovillo","year":"2002"},{"key":"ref26","series-title":"Vet Radiol Ultrasound","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1740-8261.2004.04094.x","article-title":"Contrast harmonic ultrasound of spontaneous liver nodules in 32 dogs","volume":"45","author":"O'Brien","year":"2004"},{"key":"ref27","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2460\/javma.234.1.88","article-title":"Contrast harmonic ultrasonography of splenic masses and associated liver nodules in dogs","volume":"234","author":"Ivanci\u0107","year":"2009"},{"key":"ref28","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1939-1676.2004.tb02554.x","article-title":"Magnetic resonance imaging of focal splenic and hepatic lesions in the dog","volume":"18","author":"Clifford","year":"2004"},{"key":"ref29","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"336","DOI":"10.5326\/JAAHA-MS-5603","article-title":"Concurrent splenic and right atrial mass at presentation in dogs with HSA: a retrospective study","volume":"47","author":"Boston","year":"2011"},{"key":"ref30","series-title":"Survival analysis using SAS: a practical guide","article-title":"Estimating Cox regression models with PROC PHREG","author":"Allison","year":"2010"},{"key":"ref31","series-title":"Statistics in medicine","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias","volume":"3","author":"Simon","year":"1984"},{"key":"ref32","series-title":"Crit Care","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/cc2955","article-title":"Statistics review 12: survival analysis","volume":"8","author":"Bewick","year":"2004"},{"key":"ref33","series-title":"Withrow and MacEwen's small animal clinical oncology","first-page":"463","article-title":"Tumors of skeletal system","author":"Ehrhart","year":"2013"},{"key":"ref34","series-title":"Cancer Res","first-page":"4342","article-title":"Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini","year":"2003"},{"key":"ref35","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-05-0765","article-title":"Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy","volume":"65","author":"Shaked","year":"2005"},{"key":"ref36","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/jsap.12228","article-title":"Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma","volume":"55","author":"Bracha","year":"2014"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/247\/4\/javma.247.4.393.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/247\/4\/javma.247.4.393.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/247\/4\/javma.247.4.393.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:47:39Z","timestamp":1741330059000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/247\/4\/javma.247.4.393.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,15]]},"references-count":36,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.2460\/javma.247.4.393","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8,15]]}}}